Improving survival of patients with locally advanced non-smallcell cancer remains a challenge: comment to PROCLAIM

摘要

Locally advanced non-small-cell lung cancer (NSCLC) is a heterogeneous disease with regard to biology and histopathology, location and extension of tumors, patient risk profiles and inter-institution diversities affecting both diagnostic procedures and treatments (1).